![]() |
SAE |
ISIN | NL0012044747 |
Security | SAE |
Exchange | EUREX |
Type | Option |
Options
Exp. date | Type | Type |
---|---|---|
3/21 | 40 Calls | 39 Puts |
4/21 | 23 Calls | 23 Puts |
5/21 | 12 Calls | 12 Puts |
6/21 | 23 Calls | 22 Puts |
9/21 | 22 Calls | 22 Puts |
12/21 | 23 Calls | 23 Puts |
6/22 | 15 Calls | 15 Puts |
12/22 | 14 Calls | 14 Puts |
6/23 | 13 Calls | 13 Puts |
12/23 | 13 Calls | 13 Puts |
12/24 | 13 Calls | 13 Puts |
12/25 | 11 Calls | 11 Puts |
News
- Axiom Presents “Innovating Direct-to-Patient Trials: How to use effective eClinical Solutions to enhance the success of your clinical studies” at Outsourcing in Clinical Trials West Coast 2021
02/22/2021 / 18:23 - GlobeNewswire - Worthington Industries introduces ThermaGuard™ hydrogen cylinders, a new solution for transporting and storing high-pressure hydrogen gas
02/03/2021 / 15:15 - GlobeNewswire - Ultragenyx Reports Preliminary 2020 Revenue and 2021 Revenue Guidance for Crysvita in Ultragenyx Territories
01/11/2021 / 13:00 - GlobeNewswire - Axiom Presents “Clinical Studies in 2021: The changing dynamics and challenges of getting studies done rapidly” Insights Session at Biotech Showcase Digital during JP Morgan Healthcare Conference
01/06/2021 / 18:13 - GlobeNewswire - Palvella Therapeutics Reports Top-Line Results from Pivotal Phase 2/3 VALO Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Patients with Pachyonychia Congenita
12/23/2020 / 16:23 - GlobeNewswire